Association of 25-hydroxyvitamin D level with survival outcomes in female breast cancer patients: A meta-analysis

•Prognostic value of serum vitamin D level in in female breast cancer patients is controversial.•Breast cancer patients with the lowest 25-hydroxyvitamin D level had a 57 % shorter OS.•Breast cancer patients with the lowest 25-hydroxyvitamin D levelhad a 44 % shorter BCSS.•Blood 25-hydroxyvitamin D...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of steroid biochemistry and molecular biology 2021-09, Vol.212, p.105947-105947, Article 105947
Main Authors: Li, Changyang, Li, Huijie, Zhong, Hua, Li, Xiurong
Format: Article
Language:English
Subjects:
25-Hydroxyvitamin D
Blood
Breast cancer
Clinical trials
Medical prognosis
Meta-analysis
Patients
Survival
Vitamin D
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Prognostic value of serum vitamin D level in in female breast cancer patients is controversial.•Breast cancer patients with the lowest 25-hydroxyvitamin D level had a 57 % shorter OS.•Breast cancer patients with the lowest 25-hydroxyvitamin D levelhad a 44 % shorter BCSS.•Blood 25-hydroxyvitamin D level can predict survival outcome in female breast cancer patients. Conflicting results have been reported on the association of blood vitamin D level with prognosis in women with breast cancer. This meta-analysis aimed to evaluate the association between blood 25-hydroxyvitamin D level and survival outcomes in female breast cancer patients. Two authors independently searched PubMed and Embase databases from their inception to August 25, 2020. Prospective or retrospective cohort studies evaluating the association between blood 25-hydroxyvitamin D level and survival outcomes in women with breast cancer were included. Outcome measures included overall survival (OS), breast cancer-specific survival (BCSS), and disease-free survival (DFS). Twelve studies involving 8574 female breast cancer patients were identified and analyzed. When compared the lowest with the highest category of 25-hydroxyvitamin D level, the pooled adjusted hazard ratio (HR) was 1.57 (95 % confidence interval [CI] 1.35–1.83) for OS, 1.98 (95 % CI 1.55–2.53) for DFS, and 1.44 (95 % CI 1.14–1.81) for BCSS. This meta-analysis indicates that lower blood 25-hydroxyvitamin D level is significantly associated with reduced survival among female breast cancer patients. Additional clinical trials are required to investigate whether vitamin D supplement can improve survival outcomes in these patients.
ISSN:0960-0760
1879-1220
DOI:10.1016/j.jsbmb.2021.105947